NGL Fine Chem Ltd
NGL Fine Chem Q1 FY25: Revenue ₹90.75 Cr, PAT ₹9.22 Cr
Q1 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹91Cr
- Net profit
- ₹9Cr
- Margin
- 10%
Guidance rank: #34 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on NGL Fine Chem Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1 FY25 revenue from operations: ₹90.75 crores, up 27.75% year-on-year (YoY) from ₹71.04 crores in Q1 FY24 (Page 8). Q1FY25 EBITDA: ₹9.35 crores; Year-on-Year (YoY) change: -5.20% - Q1FY25 EBITDA Margin: 10.30%; YoY change: -358 basis points - Q1FY25 Profit After Tax (PAT): ₹9.22 crores; YoY change: +8.37% - O
From NGL Fine Chem Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY25 revenue from operations: ₹90.75 crores, up 27.75% year-on-year (YoY) from ₹71.04 crores in Q1 FY24 (Page 8).
- Total income in Q1 FY25: ₹96.64 crores, a 29.95% YoY increase.
- Sales volume growth indicated through revenue, reflecting robust demand (Management Commentary, Page 6).
- Q-o-Q revenue declined 9.03% due to increased competition and traditional slower period post-Q4 FY24’s high sales (Page 8, 6).
- Outlook: Pricing pressure expected to persist into Q2 FY25 but conditions are anticipated to improve as the year progresses (Page 6).
2 more points from NGL Fine Chem Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what NGL Fine Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Greenfield expansion at Tarapur:
- Estimated capex: ₹160 crore
- Funding: Debt and internal accrual
- Status: Civil construction ongoing; ₹52.57 crore invested till Q1FY25
- Purpose: 50% capacity expansion to meet demand for new products in pipeline
- Brownfield expansion:
- Completed in subsidiary Macrotech
- Added capacities of intermediates
- Commercial production started
- Capex plans:
- Phase 1 expected completion by Q4 FY25
2 more points from NGL Fine Chem Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what NGL Fine Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
NGL Fine Chem Ltd — Quarterly revenue & net profit
NGL Fine Chem Ltd Q1 FY25 results — key figures
| ₹ Cr | Q1 FY25 | Q4 FY24 | QoQ |
|---|---|---|---|
| Revenue | 91 | 100 | -9% |
| Operating profit (EBITDA) | 9 | 16 | -43.7% |
| Operating margin | 10% | 16% | -6 pp |
| Profit before tax | 12 | 16 | -25% |
| Net profit (PAT) | 9 | 12 | -25% |
| EPS (₹) | 14.92 | 19.94 | -25.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹159 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What NGL Fine Chem's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q1 FY25)
1,746 Cr, a 9% increase YoY. Key concall takeaways from Jubilant Pharmova Ltd's Q1 FY25 earnings call — and how it ranks against sector peers.
- Shree Ganesh Rem (Q1 FY25)
Q1FY25 Revenue from Operations: ₹24.78 crore, down 8% YoY from Q1FY24's ₹26.84 crore. Key concall takeaways from Shree Ganesh Remedies Ltd's Q1 FY25 earnings…
- Themis Medicare (Q1 FY25)
122.99 Cr, up 27.26% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q1 FY25 earnings call — and how it ranks against sector peers.
- Fermenta Biotech (Q1 FY25)
Q1-FY25 consolidated operational revenue: INR 781 million, down 5.3% YoY (Q1-FY24: INR 824 million). Key concall takeaways from Fermenta Biotech Ltd's Q1 FY25…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
NGL Fine Chem Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were NGL Fine Chem Ltd Q1 FY25 results?
Q1 FY25 revenue from operations: ₹90.75 crores, up 27.75% year-on-year (YoY) from ₹71.04 crores in Q1 FY24 (Page 8). Q1FY25 EBITDA: ₹9.35 crores; Year-on-Year (YoY) change: -5.20% - Q1FY25 EBITDA Margin: 10.30%; YoY change: -358 basis points - Q1FY25 Profit After Tax (PAT): ₹9.22 crores; YoY change: +8.37% - O
What is NGL Fine Chem Ltd share price analysis?
NGL Fine Chem Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹1,711 Cr. Investors should review the full earnings analysis for detailed insights.
Is NGL Fine Chem Ltd planning capital expenditure?
Greenfield expansion at Tarapur: - Estimated capex: ₹160 crore - Funding: Debt and internal accrual - Status: Civil construction ongoing; ₹52.57 crore invested till Q1FY25 - Purpose: 50% capac
Keep NGL Fine Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.